Zinc finger protein GLI2 (GLI2)

Zinc finger protein GLI2 (GLI2) is a transcription factor of the C2H2-type zinc finger protein family, encoded by the GLI2 gene in humans[1]. It acts as a key mediator of the Sonic hedgehog (Shh) pathway, exerting both transcriptional activator and repressor functions to regulate target gene expression during embryogenesis, tissue patterning, and homeostasis[1][2][3][6]. GLI2 is implicated as a potent oncogene in multiple malignancies, including prostate and pancreatic cancers, basal cell carcinoma, and certain hematological cancers[2][3][6]. It is essential for craniofacial, pituitary, immune, and cardiac development; mutations can cause a spectrum of congenital disorders including hypopituitarism and holoprosencephaly[1][5][7]. GLI2-driven activation upregulates genes involved in cell cycle progression (e.g., cyclin D1), proliferation, and survival, while its inhibition can induce cell cycle arrest and apoptosis. Pharmacological inhibition of GLI2, either directly or through pathway inhibition (e.g., cyclopamine, GANT61), is an area of active investigation for therapeutic purposes[2][4][6].

Other names

GLI family zinc finger 2GLI-Kruppel family member 2GLI2 transcription factor

Inhibition of GLI2 prevents its transcriptional activator/repressor functions and downstream gene activation in the Hedgehog pathway, blocking cell proliferation and promoting apoptosis in cancer cells. Drugs may interfere with upstream regulators like TGF-β or β-catenin to suppress GLI2-driven transcription.